| Cash Flow | 2025-10-31 |
|---|---|
| Net loss and comprehensive loss | -483,447 |
| Stock-based compensation | 0 |
| Financing costs | 507,368 |
| Allowance for research and development rebate due | 0 |
| Change in fair value of derivative liability | 422,419 |
| Amortization of debt discount and closing costs | 39,601 |
| Loss from change in fair value of oragenics, inc. common stock | 0 |
| Financing costs paid with issuance of common stock | 1,750 |
| Increase in prepaid expenses and other current assets | 87,397 |
| Increase in accounts payable and accrued wages | 73,285 |
| Increase in accounts payable and accrued wages, officers | 32,308 |
| Increase in accrued interest | 54,953 |
| Net cash used in operating activities | -283,998 |
| Net proceeds from notes payable | 290,500 |
| Net cash provided by financing activities | 290,500 |
| Net increase in cash and cash equivalents | 6,502 |
| Cash and cash equivalents at beginning of period | 19,084 |
| Cash and cash equivalents at end of period | 25,586 |
Odyssey Health, Inc. (ODYY)
Odyssey Health, Inc. (ODYY)